GLP-1 Medications and Cancer: Do They Raise or Lower Your Risk?

Few questions about GLP-1 medications cause more worry than cancer. Every one of these drugs carries a boxed warning about thyroid cancer, and headlines pull in both directions. Yet a large and growing body of evidence suggests that, far from causing cancer, these medications may actually lower the risk of many cancers linked to obesity. Both things can be partly true — and understanding the difference matters.

This is the cancer chapter of our GLP-1 series. Here is what the randomized trials show, what the large observational studies suggest, how to think about the thyroid warning, and where the honest uncertainty lies.

Why Obesity and Cancer Are Connected

To make sense of this topic, start with the fact that obesity is itself a cancer risk factor. Excess body weight is linked to at least 13 types of cancer, including cancers of the endometrium (uterus), esophagus, liver, stomach, kidney, pancreas, colon and rectum, gallbladder, ovary, thyroid, and postmenopausal breast, as well as meningioma and multiple myeloma (Taranto et al., Nature Reviews Cancer, 2024).

The reasons overlap with the themes throughout this series. Excess fat tissue produces inflammatory signals, drives insulin resistance and high insulin levels (which can promote cell growth), raises estrogen (which fuels some cancers), and weakens the immune system's ability to police abnormal cells. Because weight loss reverses many of these processes — and bariatric surgery, which produces large durable weight loss, has been shown to reduce cancer risk and cancer death — the key question is whether GLP-1 medications, which now produce substantial weight loss, deliver similar protection.

The Randomized Trial Data: Reassuring on Overall Risk

The highest-quality evidence comes from randomized controlled trials, where people are randomly assigned to the drug or placebo. A systematic review and meta-analysis published in the Annals of Internal Medicine pooled dozens of placebo-controlled trials including tens of thousands of participants. Its conclusion: GLP-1 receptor agonists probably have little or no effect on the risk of thyroid, pancreatic, breast, or kidney cancer (moderate certainty), and likely little or no effect on several other cancers (Anderson et al., Annals of Internal Medicine, 2025). In plain terms, the randomized evidence does not show that these drugs cause cancer.

A 2026 review in Nature Reviews Clinical Oncology reached a similar practical conclusion: the overall risk–benefit profile of GLP-1 receptor agonists remains favorable for people with type 2 diabetes and obesity, while noting that longer follow-up is still needed because most trials were not designed primarily to detect cancer (Kurtzman et al., Nature Reviews Clinical Oncology, 2026).

The Observational Data: A Signal Toward Protection

When researchers look at very large real-world databases — which follow more people for longer than trials do — the signal actually points toward lower cancer risk. Multiple large cohort studies have found that people with type 2 diabetes taking GLP-1 medications have lower rates of obesity-related cancers than those on other diabetes drugs, with the effect appearing more pronounced at higher body weights (Taranto et al., Nature Reviews Cancer, 2024). Some analyses have reported notable reductions in specific obesity-associated cancers, such as colorectal and liver cancer.

The essential caveat: these are observational studies. They cannot prove cause and effect, because people who take these drugs may differ in many ways from those who do not. But the consistency, size, and biological plausibility of the signal make it noteworthy — and it aligns with what is known about weight loss and cancer.

How GLP-1 Drugs Might Lower Cancer Risk

Beyond weight loss, several mechanisms could plausibly contribute. GLP-1 medications lower insulin and reduce insulin resistance (less growth-promoting signaling), calm chronic inflammation (a known cancer driver, covered in the inflammation chapter), and may improve immune surveillance — the immune system's ability to detect and destroy abnormal cells (Taranto et al., Nature Reviews Cancer, 2024). Laboratory studies have shown anti-growth effects in several cancer cell types. Importantly, context matters: the same signaling could, in theory, be unhelpful in certain rare tumor types, which is one reason researchers urge caution rather than blanket claims.

The Thyroid Cancer Question

Now the concern that generates the most anxiety. Every GLP-1 medication carries a boxed warning about medullary thyroid cancer, a rare thyroid cancer. Where did it come from?

The warning is based on rodent studies, in which GLP-1 drugs caused thyroid C-cell tumors in rats and mice in a dose- and duration-dependent way. But there are important species differences: rodent thyroid C-cells carry far more GLP-1 receptors than human C-cells, and in humans these drugs do not meaningfully raise calcitonin, the blood marker of C-cell activity (Anderson et al., Annals of Internal Medicine, 2025). Whether the rodent finding applies to people is genuinely uncertain.

The human evidence is mixed and, on balance, does not show a clear increase. Large cohort studies have generally found no increased thyroid cancer risk, though a few analyses have raised a small signal that may reflect closer medical surveillance (people on these drugs get more medical attention, so more incidental cancers are found). In the pooled randomized data, any effect was small and not statistically significant, and the absolute risk — if it exists at all — is very low (Anderson et al., Annals of Internal Medicine, 2025).

The practical bottom line: the boxed warning remains appropriate for people with a personal or family history of medullary thyroid cancer or the genetic syndrome MEN2, and these medications are contraindicated in those individuals. For the general population, the thyroid risk does not appear to outweigh the substantial heart, kidney, liver, and metabolic benefits.

Emerging — and Preliminary — Data in People With Cancer

The newest and most speculative research asks whether GLP-1 drugs might help people who already have cancer — by slowing progression, improving survival, or making treatments like immunotherapy work better. Some retrospective analyses and conference reports have suggested associations with reduced progression or better outcomes across several tumor types (Kurtzman et al., Nature Reviews Clinical Oncology, 2026).

These findings are hypothesis-generating only. They come from looking backward at existing records, are prone to bias, and have not been confirmed in prospective trials. They should not influence cancer treatment decisions today. They are, however, a reason the field is watching closely and designing proper studies.

The Bottom Line

The randomized trial evidence does not show that GLP-1 medications increase overall cancer risk, and large observational studies suggest they may reduce the risk of obesity-related cancers — consistent with what weight loss and reduced inflammation would predict. The one genuine caution is thyroid cancer: a boxed warning based on rodent data, with weak human evidence and very low absolute risk, but a firm contraindication for people with medullary thyroid cancer or MEN2. Emerging data on cancer treatment are intriguing but far too preliminary to act on. For the large majority of people with obesity or type 2 diabetes, the cancer picture is reassuring — and, as always, worth reviewing with your physician in light of your personal and family history.